Trial of efficacy and safety of NS-229 versus placebo in patients with Eosinophilic Granulomatosis

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis with Polyangiitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230526

Enrollment

Registered

2023-12-21

Start date

2024-05-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eosinophilic granulomatosis with polyangiitis(EGPA)

Interventions

Subjects receive multiple oral doses of NS-229 or placebo.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Male or female subjects aged >=18 years at the time the informed consent form is signed (2)Diagnosis of EGPA (3)Subjects receive background OGC dose of>=7.5 mg/day with or without stable treatment with mepolizumab or benralizumab.

Exclusion criteria

Exclusion criteria: (1) Current diagnosis of either granulomatosis with polyangiitis or microscopic polyangiitis (2) Imminently life-threatening EGPA disease

Design outcomes

Primary

Measure	Time frame
The proportion of subjects in remission (oral glucocorticoid [OGC] 4.0)* at Week 28 of the study treatment period. *Definition of remission (OGC 4.0): Birmingham Vasculitis Activity Score (BVAS) of 0 AND OGC dose of prednisolone/prednisone <=4.0 mg/day.	—

Countries

Canada, France, Germany, Italy, Japan, Spain, UK, US

Contacts

Public ContactOperations Clinical

Nippon Shinyaku Co., Ltd.

zz_mail_clinical-trials@po.nippon-shinyaku.co.jp+81-120-40-8930

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026